Efficacy of high-flow nasal oxygenation against peri- and post-procedural hypoxemia in patients with obesity: a meta-analysis of randomized controlled trials

doi:10.1038/s41598-022-10396-5

CNU IR > College of Smart Living > Dept. of Hospital and Health (including master's program) > Periodical Articles > Item 310902800/34696

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34696

Title:	Efficacy of high-flow nasal oxygenation against peri- and post-procedural hypoxemia in patients with obesity: a meta-analysis of randomized controlled trials
Authors:	Hung, Kuo-Chuan Ko, Ching-Chung Chang, Po-Chih Wang, Kuei-Fen Teng, I-Chia Lin, Chien-Hung Huang, Ping-Wen Sun, Cheuk-Kwan
Contributors:	Chi Mei Hospital Department of Hospital and Health Care Administration, Chia Nan University of Pharmacy & Science Department of Health and Nutrition, Chia Nan University of Pharmacy & Science Kaohsiung Medical University Kaohsiung Medical University Hospital Show Chwan Memorial Hospital E-Da Hospital I Shou University
Keywords:	preoxygenation atelectasis intubation cannula anesthesia management therapy
Date:	2022
Issue Date:	2023-12-11 14:05:39 (UTC+8)
Publisher:	NATURE PORTFOLIO
Abstract:	This meta-analysis aimed at investigating the efficacy of high-flow nasal oxygenation (HFNO) against hypoxemia in patients with obesity compared with conventional oxygenation therapy and non-invasive ventilation. Databases were searched from inception to August 2021. Studies involving peri- or post-procedural use of HFNO were included. The primary outcome was risk of hypoxemia, while the secondary outcomes included status of oxygenation and carbon dioxide elimination. Ten randomized controlled trials (RCTs) were included. We found that HFNO prolonged the safe apnea time at induction compared to control group [mean difference (MD) = 73.88 s, p = 0.0004; 2 RCTs] with no difference in risk of peri-procedural hypoxemia [relative risk (RR) = 0.91, p = 0.64; 4 RCTs], minimum SpO2 (MD = 0.09%, p = 0.95; 4 RCTs), PaO2 (MD = - 8.13 mmHg, p = 0.86; 3 RCTs), PaCO2 (MD = - 6.71%, p = 0.2; 2 RCTs), EtCO2 (MD = - 0.28 mmHg, p = 0.8; 4 RCTs) between the two groups. HFNO also did not improve postprocedural PaO2/FiO2 ratio (MD = 41.76, p = 0.58; 2 RCTs) and PaCO2 (MD = - 2.68 mmHg, p = 0.07; 2 RCTs). This meta-analysis demonstrated that the use of HFNO may be associated with a longer safe apnea time without beneficial impact on the risk of hypoxemia, oxygenation, and CO2 elimination in patients with obesity. The limited number of trials warranted further large-scale studies to support our findings.
Relation:	Scientific Reports, v.12, n.1, Article 6448
Appears in Collections:	[Dept. of Hospital and Health (including master's program)] Periodical Articles [Dept. of Health and Nutrition (including master's program)] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	165	View/Open
s41598-022-10396-5.pdf		4037Kb	Adobe PDF	89	View/Open

Loading...